Section 1: Core Components of Antimicrobial Stewardship 1. Introduction to Antimicrobial Stewardship 2. Implementation of Antimicrobial Stewardship Program 2.1. Core Elements of AMS Program 2.2. Steps of Implementation of AMS Program in a Hospital 2.3. Role of Information Technology in AMS Program 2.4. AMS Interventions 2.5. Role of Behavioral Change in AMS 3. Monitoring of Antimicrobial Stewardship 4. Current Scenario of Antimicrobial Resistance and Role of AMR Surveillance Section 2: Diagnostic Stewardship ...
Read More
Section 1: Core Components of Antimicrobial Stewardship 1. Introduction to Antimicrobial Stewardship 2. Implementation of Antimicrobial Stewardship Program 2.1. Core Elements of AMS Program 2.2. Steps of Implementation of AMS Program in a Hospital 2.3. Role of Information Technology in AMS Program 2.4. AMS Interventions 2.5. Role of Behavioral Change in AMS 3. Monitoring of Antimicrobial Stewardship 4. Current Scenario of Antimicrobial Resistance and Role of AMR Surveillance Section 2: Diagnostic Stewardship 5. Introduction to Diagnostic Stewardship 6. Role of Appropriate Specimen Collection 7. Role of Direct Microscopy 8. Accurate Processing of Clinical Specimens and Reporting of Cultures 9. Role of Accurate Microbial Identification 10. Basics of Antimicrobial Susceptibility Testing 11. Interpretation of Antimicrobial Susceptibility Testing 12. Detection of Specific Antimicrobial Resistance 13. Quality Control in Antimicrobial Susceptibility Testing 14. Direct Susceptibility Testing 15. Selective Reporting and Role of Breakpoint-to-MIC Quotient 16. Comments in Clinical Microbiology Reporting 17. Role of Biomarkers and Point-of-care Tests (POCT) in AMS Section 3: Hospital Antibiogram 18. Introduction to Antibiogram 19. Routine Antibiogram 20. Specialized Antibiograms 21. Use of Antibiogram 22. Analysis of MDR/XDR/PDR Phenotypes Section 4: Antimicrobial Agents 23. Antimicrobial Agents: Classification and PK-PD Considerations 24. Cell Wall Active Agents-I: B-lactams 25. Cell Wall Active Agents-II: Glycopeptides and Fosfomycins 26. Cell Membrane Acting Agents: Polymyxins and Daptomycin 27. Protein Synthesis Inhibitors: Aminoglycosides, Tetracyclines, Glycylcyclines, Macrolides, Lincosamides, Oxazolidinones, Streptogramins, Chloramphenicol and Others 28. Nucleic Acid, Folic Acid Synthesis Inhibitors and Others: Quinolones, Nitroimidazoles, Nitrofurans, Cotrimoxazole and Topical Agents 29. Antitubercular Drugs and Treatment Guidelines 30. Antiviral Drugs 31. Antifungal Drugs 32. Antiparasitic Drugs Section 5: Antimicrobial Therapy (Clinical Stewardship) 33. Empirical Antimicrobial Therapy 33.1. Cardiovascular Infections 33.2. Sepsis and Bloodstream Infections 33.3. Central Nervous System Infections 33.4. Intra-abdominal Infections 33.5. Skin and Soft Tissue Infections 33.6. Respiratory Tract Infections 33.7. Genito-urinary Tract Infections 33.8. Bone and Joint Infections 33.9. Post-cardiovascular Surgery Infections 33.10. Ocular Infections 33.11. Ear Infections 33.12. Burn Wound Infections 33.13. Antimicrobial Policy in Febrile Neutropenia 33.14. Infections in Solid Organ Transplant Recipients (Non-neutropenic Settings) 33.15. Pediatric Infections 33.16. Neonatal Infections 34. Targeted Antimicrobial Therapy for Gram-positive Bacterial Infections 35. Targeted Antimicrobial Therapy for Gram-negative Bacterial Infections 36. Antifungal Stewardship and Treatment of Fungal Infections 37. Antimicrobial Prophylaxis Section 6: Miscellaneous 38. Antimicrobial Stewardship in Special Situations 38.1. AMS in Outpatient Setting 38.2. AMS in Outpatient Parenteral Antimicrobial Therapy (OPAT) Settings 38.3. AMS in Long-term Care Facility Setting 38.4. AMS in Critical Care Units 38.5. AMS in Immunocompromised Patients 38.6. AMS in Pediatric Units 38.7. AMS in Community Hospitals 39. One Health Approach in Antimicrobial Stewardship 40. Hospital Sou
Read Less